Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER vs AMMONUL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Isolyte E with Dextrose 5% provides isotonic fluid, electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate), and calories (dextrose). Dextrose supplies glucose for cellular energy, electrolytes maintain acid-base balance and osmotic pressure, and acetate/gluconate serve as bicarbonate precursors to correct metabolic acidosis.
Ammonul (sodium phenylacetate and sodium benzoate) provides an alternative pathway for nitrogen excretion. Phenylacetate conjugates with glutamine to form phenylacetylglutamine, which is excreted by the kidneys. Benzoate conjugates with glycine to form hippurate, which is also excreted renally. This reduces ammonia levels in patients with urea cycle disorders.
Fluid and electrolyte replacement in patients with normal or mildly depleted intravascular volume,Treatment and prevention of hypokalemia,Metabolic acidosis correction,Caloric supplementation when peripheral parenteral nutrition is indicated
FDA: Adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with urea cycle disorders.,Off-label: Management of hyperammonemia due to other causes (e.g., valproate toxicity, organic acidemias).
Intravenous infusion; dose based on electrolyte deficits and maintenance requirements; typical adult maintenance: 50-100 m L/hour, up to 2-3 L/day.
For acute hyperammonemia: 2.5 g/m² IV over 90 minutes, followed by continuous IV infusion at 2.5 g/m² over 24 hours. For maintenance: 2.5 g/m² IV or oral every 6 hours.
Not applicable (dextrose and electrolytes are endogenous substances; distribution and elimination are rapid, with a functional half-life of minutes to hours depending on infusion rate and renal function).
Phenylacetate: 0.5-1 hour; phenylacetylglutamine: 1-2 hours. Clinical context: rapid clearance; requires continuous IV infusion for sustained effect.
Dextrose is metabolized via glycolysis and the citric acid cycle. Acetate is metabolized primarily in the liver and muscle to bicarbonate. Gluconate is converted to glucose or metabolized via the pentose phosphate pathway.
Sodium phenylacetate is metabolized via conjugation with glutamine (by glutamine N-phenylacetyltransferase) to form phenylacetylglutamine. Sodium benzoate is metabolized via conjugation with glycine (by benzoyl-Co A:glycine N-acyltransferase) to form hippurate. Both conjugates are rapidly excreted by the kidneys.
Renal: 100% (as free water and electrolytes, not metabolized). Biliary/Fecal: negligible.
Renal: >80% (primarily as phenylacetylglutamine). Biliary/fecal: <5%.
Negligible (<5%) for dextrose and electrolytes; no specific binding proteins.
Phenylacetate: 82% bound to albumin; phenylacetylglutamine: 51% bound.
Dextrose: ~0.2 L/kg (total body water); Electrolytes: ~0.4 L/kg (extracellular fluid). Clinical meaning: distributes throughout total body water.
Phenylacetate: 0.3-0.5 L/kg; phenylacetylglutamine: 0.1-0.2 L/kg. Indicates distribution primarily in extracellular fluid.
Intravenous: 100%.
Oral: Not available; sodium phenylacetate/sodium benzoate is administered intravenously only.
Monitoring of electrolytes and volume status required; dosage adjustment not standardized; avoid in severe renal impairment (e GFR <30 m L/min/1.73 m²) due to risk of hyperkalemia and fluid overload.
Contraindicated in severe renal insufficiency (Cr Cl <30 m L/min). For moderate impairment (Cr Cl 30-50 m L/min): reduce dose by 50%. For mild impairment (Cr Cl 50-80 m L/min): no adjustment needed.
No specific adjustment recommended; monitor electrolytes and acid-base balance; caution in severe hepatic impairment due to altered fluid clearance.
No specific guidelines based on Child-Pugh; use with caution in severe hepatic impairment. Monitor ammonia levels.
Weight-based: 100-150 m L/kg/day for maintenance; adjust for ongoing losses; use with caution in neonates and children with renal impairment.
Same weight-based area (2.5 g/m²) as adults. For neonates and infants, dosage calculated per body surface area. Administration route and frequency identical to adults.
Consider reduced starting rates due to decreased renal function and increased risk of fluid overload; monitor electrolytes and volume status closely; adjust rate based on comorbidities.
No specific dose adjustment; use caution due to age-related renal decline. Monitor renal function and ammonia levels.
NOT FOR USE IN HYPERLACTATEMIA, SEVERE METABOLIC ALKALOSIS, OR SEVERE HEPATIC FAILURE; CONTAINS ALUMINUM WHICH MAY BE TOXIC WITH PROLONGED USE IN RENAL IMPAIRMENT; ADDITIVES MAY BE INCOMPATIBLE, CONSULT PHARMACIST.
Ammonul must be administered with arginine to prevent arginine deficiency and worsening hyperammonemia. Neurotoxicity (including seizures, cerebral edema, and death) may occur if not properly monitored. Extravasation can cause severe tissue necrosis; ensure proper IV access.
Monitor serum electrolytes, fluid balance, and blood glucose. Use with caution in patients with heart failure, renal impairment, hepatic disease, or hyperglycemia. Hypersensitivity reactions may occur. Avoid rapid or large-volume infusion in patients with impaired glucose tolerance.
Monitor plasma ammonia levels, electrolytes, and blood counts closely.,Risk of hypernatremia (high sodium load); adjust fluid and sodium intake.,Extravasation risk: administer through a central line if possible; treat extravasation immediately.,May cause hyperventilation and metabolic acidosis.,Use with caution in patients with hepatic or renal impairment.,Contains sodium benzoate; possible hypersensitivity reactions.
Hypernatremia, hyperkalemia, hypermagnesemia, hypercalcemia, hyperlactatemia, severe metabolic alkalosis, severe hepatic failure, hyperglycemic states, anuria, or known hypersensitivity to any component.
Known hypersensitivity to any component of Ammonul.,Pre-existing severe hypernatremia.,Concomitant use with other drugs containing sodium benzoate or sodium phenylacetate.
No known food interactions. However, patients with diabetes should be aware of dextrose content which affects blood glucose. Dietary potassium or magnesium restriction may be necessary if electrolyte imbalances occur.
Take with food or meals to reduce gastrointestinal distress. Avoid high-protein supplements or foods that may increase ammonia levels; dietary protein restriction should be managed by a dietitian.
No evidence of teratogenicity in animal studies or human data. Dextrose and electrolytes are essential nutrients; no structural anomalies attributed. However, hyperglycemia in uncontrolled maternal diabetes may cause fetal malformations. Use cautiously in gestational diabetes.
Pregnancy Category C. No adequate human studies; in animal studies, sodium phenylacetate/sodium benzoate caused fetal toxicity at maternally toxic doses. First trimester: potential risk unknown; second/third trimester: may cause maternal ammonia accumulation if subtherapeutic, but drug is essential for urea cycle disorders. Risk of untreated hyperammonemia outweighs potential teratogenic risk.
Dextrose and electrolytes pass into breast milk but are normal milk constituents. No adverse effects expected in term infants. M/P ratio not determined as these are endogenous substances. Consider maternal fluid/electrolyte status.
No human data on excretion in breast milk; M/P ratio unknown. Caution advised; consider risk of infant hyperammonemia vs. benefit of breastfeeding.
No specific dose adjustment needed. Monitor for volume expansion in pregnancy (increased intravascular space). Adjust rate based on maternal glucose, electrolytes, and clinical response. Avoid excess dextrose in gestational diabetes.
Monitor ammonia levels closely; pregnancy may increase metabolic demands. Dose adjustments based on ammonia levels: usual dose is weight-based (e.g., 5.5 g/m²/day for sodium phenylacetate/sodium benzoate). Consider increased clearance during pregnancy? No specific data; empiric adjustments based on ammonia levels recommended.
ISOLYTE E W/ DEXTROSE 5% is an isotonic, balanced electrolyte solution with 5% dextrose for parenteral replacement of fluid and electrolytes. It contains potassium, magnesium, and acetate (bicarbonate precursor). Avoid in patients with hyperkalemia, hypermagnesemia, or metabolic alkalosis. Monitor serum electrolytes, glucose, and renal function. Use with caution in heart failure, renal impairment, and patients at risk for fluid overload. Do not administer if cloudy or precipitate present. Discard any unused portion.
AMMONUL (sodium phenylbutyrate) is used as a nitrogen-binding agent in urea cycle disorders. Monitor plasma ammonia levels closely; target <60 μmol/L. Administer with food to reduce GI irritation. Not recommended in patients with severe hepatic impairment due to reduced conversion to phenylacetate. Contraindicated in pregnancy (category C).
This solution provides fluids, sugar, and electrolytes to correct imbalances.,Your healthcare team will monitor your blood sugar and electrolyte levels during treatment.,Report any symptoms like swelling, shortness of breath, or changes in urination.,This medication is given only in a hospital or clinic setting by a healthcare professional.,Tell your doctor if you have any allergies, especially to corn (dextrose source).
Take exactly as prescribed; do not skip doses.,May cause nausea, vomiting, or diarrhea; take with food.,Avoid use of valproic acid or corticosteroids unless directed.,Contact provider if symptoms of hyperammonemia occur (vomiting, lethargy, confusion).,Women of childbearing potential should use effective contraception.,Store at room temperature away from moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER vs AMMONUL, answered by our medical review team.
ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte E with Dextrose 5% provides isotonic fluid, electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate), and calories (dextrose). Dextrose supplies glucose for cellular energy, electrolytes maintain acid-base balance and osmotic pressure, and acetate/gluconate serve as bicarbonate precursors to correct metabolic acidosis.. AMMONUL is a Ammonia Detoxicant that works by Ammonul (sodium phenylacetate and sodium benzoate) provides an alternative pathway for nitrogen excretion. Phenylacetate conjugates with glutamine to form phenylacetylglutamine, which is excreted by the kidneys. Benzoate conjugates with glycine to form hippurate, which is also excreted renally. This reduces ammonia levels in patients with urea cycle disorders.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER and AMMONUL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; dose based on electrolyte deficits and maintenance requirements; typical adult maintenance: 50-100 m L/hour, up to 2-3 L/day.. The standard adult dose of AMMONUL is: For acute hyperammonemia: 2.5 g/m² IV over 90 minutes, followed by continuous IV infusion at 2.5 g/m² over 24 hours. For maintenance: 2.5 g/m² IV or oral every 6 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER and AMMONUL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. No evidence of teratogenicity in animal studies or human data. Dextrose and electrolytes are essential nutrients; no structural anomalies attributed. However, hyperglycemia in unco. AMMONUL is classified as Category C. Pregnancy Category C. No adequate human studies; in animal studies, sodium phenylacetate/sodium benzoate caused fetal toxicity at maternally toxic doses. First trimester: potential. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.